Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Graves' disease
ISRCTN20381716Phase 2Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Graves' disease and hyperthyroidism, sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Remission at 2 years. Started Nov 2016; status: completed.
02
Drugs
rituximab
03
Conditions
Graves' diseasehyperthyroidism
Beyond the preview
Go deeper on ISRCTN20381716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN20381716.